This study tested the hypothesis that the expression of CD112 and CD155 (DNAM-1 ligands) on leukemic blasts induces a decreased expression of the activating receptor DNAM-1 on natural killer (NK) cells from acute myeloid leukemia (AML) patients. DNAM-1 is a co-receptor involved in the activation of NK cell cytotoxicity after its interaction with its ligands CD112 and CD155 on target cells. Here we study the expression of DNAM-1 on NK cells and DNAM-1 ligands on blasts from AML patients stratified by age. The results demonstrate that NK cells from AML patients younger than 65 years have a reduced expression of DNAM-1 compared with age-matched controls. The analysis of DNAM-1 ligands showed a high expression of CD112 and CD155 on leukemic blasts. An inverse correlation between CD112 expression on leukemic blasts and DNAM-1 expression on NK cells was found. Furthermore, downregulation of DNAM-1 was induced on healthy donors' NK cells after in vitro culture with leukemic blasts expressing DNAM-1 ligands. In conclusion, these results support the hypothesis that receptor-ligand crosslinking downregulates DNAM-1 expression on NK cells from patients o65 years of age. Considering the relevance of DNAM-1 in NK recognition and killing of leukemic cells, the reduced expression of this receptor on NK cells from AML patients can represent an additional mechanism of tumor escape. Keywords: acute myeloid leukemia; aging; cancer; DNAM-1; natural killer cells Natural killer (NK) cells are lymphocytes of the innate immune system specialized in the recognition and lysis of tumors and virus-infected cells. 1 NK cell function is dictated by the balance of signals from inhibitory and activating receptors on the surface of NK cells that recognize their ligands on target cells. [1][2][3][4][5][6] Activating signals are mediated by a wide array of receptors, including, among others, NKG2D, natural cytotoxicity receptors, which include NKp30, NKp46 and NKp44 and DNAX accessory molecule-1 (DNAM-1, also known as CD226). The DNAM-1 receptor is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. In humans, DNAM-1 is expressed on NK, T cells, monocytes, a subset of B cells 7 and platelets. 8 Stimulation of DNAM-1 by its interaction with its ligands CD155 (poliovirus receptor) and CD112 (Nectin-2) leads to NK-cell activation and target cell lysis. 9-12 DNAM-1 ligands can be expressed on different types of tumors, including leukemia, myeloma, ovarian carcinoma and melanoma. [13][14][15][16] Thus, previous data support the involvement of DNAM-1 in the lysis of leukemic blasts mediated by NK cells. 13 Accumulating evidences strongly support a role for NK cells in the anti-tumor response against hematological malignancies. 5,17-19 Acute myeloid leukemia (AML) is generally considered a disease of older adults as more than half of AML patients are over the age 65 years at diagnosis. In addition, age has a profound impact in the prognosis of AML patients, as refractoriness of the disease and frailty of this population contributes...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.